• Antonio Lee
  • Global Head
  • MEDIPOST

Curriculum Vitae

Education

1999 : B.Sc. (Hons) University of Otago, New Zealand.
2001 : M.Sc. University of Otago, New Zealand.
2002 : Postgraduate Fellowship, University of Cardiff, Wales, U.K.
2006 : Ph.D. (Developmental & Stem Cell Biology) University of Otago, New Zealand.

Professional Experience

2017 – current : Global Head, Business Development, MEDIPOST Co., Ltd. Korea.
2013 – current : CEO & Managing Director, MEDIPOST America Inc. U.S.A.
2011 – 2013 : Associate Director, Business Development, MEDIPOST Co., Ltd. Korea.
2009 – 2011 : Research Scientist, School of Medical Sciences, University of New South Sales, Sydney, Australia.
2006 – 2008 : Postdoctoral Research Fellow, The Children’s Hospital at Westmead, Sydney, Australia

Research Interests

Regenerative Medicine & Cell Biology

Honors & Awards

Publications

Lee AS, Kahatapitiya P, Kramer B, Joya JE, Hook J, Liu R, Schevzov G, Alexander IE, McCowage G, Montarras D, Gunning PW, Hardeman EC. Stem Cells 2009:27 (5): 1098-1108
Lee AS, Anderson JE, Joya JE, Head SI, Pather N, Kee AJ, Gunning PW and Hardeman EC. BioArchitecture 2013:3:2, 25-37
Lee AS, Harris J, Bate M, Vijayraghavan K, Fisher L, Tajbakhsh S and Duxson M. Dev Dyn 2013:1043-1055

Abstract

Cell & Gene Therapy Outlook in Korea

Since 2011, South Korea has approved 4 autologous and allogeneic Stem Cell Therapy products with BLA (Biologics License Application). The Ministry of Food and Drug Safety (MFDS) of Korea, has ample regulatory experience in the field of cell and gene therapy including the more recent approval of gene-modified allogeneic cell therapy product in 2017. Combined with high quality clinical study sites and infrastructure, Korean market will be attracting foreign cell and gene therapy product developers in coming years. Case studies on commercial-stage cell and gene therapy products launched in South Korean market will be shared.